[11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 9, 2013, Pages 1406-1419

  Su, Zhangjie ^a   Herholz, Karl ^a   Gerhard, Alexander ^a   Roncaroli, Federico ^b   Du Plessis, Daniel ^c   Jackson, Alan ^a   Turkheimer, Federico ^d   Hinz, Rainer ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b John Fulcher Neuro Oncology Lab   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

11C (R)PK11195; Glioma; Kinetic analysis; PET; Reference tissue; Translocator protein

Indexed keywords

CARRIER PROTEIN; GADOLINIUM; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; TRACER; (R) (11C)1 (2 CHLOROPHENYL) N METHYL N (1 METHYLPROPYL) 3 ISOQUINOLINECARBOXAMIDE; (R)-(11C)1-(2-CHLOROPHENYL)-N-METHYL-N-(1-METHYLPROPYL)-3-ISOQUINOLINECARBOXAMIDE; 4 AMINOBUTYRIC ACID RECEPTOR; AMIDE; DIAGNOSTIC AGENT; ISOQUINOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TSPO PROTEIN, HUMAN; PROTEIN BINDING;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BINDING KINETICS; BRAIN TISSUE; CANCER GRADING; CLINICAL ARTICLE; CLINICAL PRACTICE; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; GLIOMA; GRAY MATTER; HEMISPHERE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; TISSUE SECTION; WHITE MATTER; BRAIN TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; GENETICS; METABOLISM; PROTEIN BINDING; SCINTISCANNING; STANDARD; TISSUE DISTRIBUTION; DIAGNOSTIC USE; STANDARDS;

AMIDES; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; GLIOMA; ISOQUINOLINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, GABA; REFERENCE STANDARDS; TISSUE DISTRIBUTION;

EID: 84881664767     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2447-2     Document Type: Article

References (58)

1. Kassiou M, Meikle SR, Banati RB. Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Res Brain Res Rev. 2005;48:207-10.
2. Schuitemaker A, van Berckel BN, Kropholler MA, Veltman DJ, Scheltens P, Jonker C, et al. SPM analysis of parametric (R)-[11C]PK11195 binding images: plasma input versus reference tissue parametric methods. Neuroimage. 2007;35:1473-9.
3. Banati RB. Visualising microglial activation in vivo. Glia. 2002;40:206-17.
4. Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158-67.
5. Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol. 2008;35:306-28.
6. Shah F, Hume SP, Pike VW, Ashworth S, McDermott J. Synthesis of the enantiomers of [N-methyl-11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol. 1994;21:573-81.
7. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. 2000;123(Pt 11):2321-37.
8. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461-7.
9. Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003;61:686-9.
10. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage. 2005;24:591-5.
11. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Imaging microglial activation in Huntington's disease. Brain Res Bull. 2007;72:148-51.
12. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308-22.
13. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21:404-12.
14. Kropholler MA, Boellaard R, Schuitemaker A, van Berckel BN, Luurtsema G, Windhorst AD, et al. Development of a tracer kinetic plasma input model for (R)-[11C]PK11195 brain studies. J Cereb Blood Flow Metab. 2005;25:842-51.
15. Kropholler MA, Boellaard R, Schuitemaker A, Folkersma H, van Berckel BN, Lammertsma AA. Evaluation of reference tissue models for the analysis of [11C](R)-PK11195 studies. J Cereb Blood Flow Metab. 2006;26:1431-41.
16. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-8.
17. Schuitemaker A, van Berckel BN, Kropholler MA, Kloet RW, Jonker C, Scheltens P, et al. Evaluation of methods for generating parametric (R-[11C]PK11195 binding images. J Cereb Blood Flow Metab. 2007;27:1603-15.
18. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279-87.
19. Tomasi G, Edison P, Bertoldo A, Roncaroli F, Singh P, Gerhard A, et al. Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease. J Nucl Med. 2008;49:1249-56.
20. Kropholler MA, Boellaard R, van Berckel BN, Schuitemaker A, Kloet RW, Lubberink MJ, et al. Evaluation of reference regions for (R)-[(11)C]PK11195 studies in Alzheimer's disease and mild cognitive impairment. J Cereb Blood Flow Metab. 2007;27:1965-74.
21. Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology. 1999;53:2199-203.
22. Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. 2001;124:2014-27.
23. Doble A, Malgouris C, Daniel M, Daniel N, Imbault F, Basbaum A, et al. Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: anatomical and subcellular distribution. Brain Res Bull. 1987;18:49-61.
24. Ashburner J, Haslam J, Taylor G, Cunningham VJ, Jones T. A cluster analysis approach for the characterization of dynamic PET data. In: Myers R, Cunningham V, Bailey D, Jones T, editors. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic; 1996. p. 301-6.
25. Myers R, Gunn RN, Cunningham VJ, Banati RB, Jones T. Cluster analysis and the reference tissue model in the analysis of clinical [11C]PK11195 PET. J Cereb Blood Flow Metab. 1999;19:S789.
26. Yaqub M, van Berckel BN, Schuitemaker A, Hinz R, Turkheimer FE, Tomasi G, et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32:1600-8.
27. Miettinen H, Kononen J, Haapasalo H, Helen P, Sallinen P, Harjuntausta T, et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res. 1995;55:2691-5.
28. Vlodavsky E, Soustiel JF. Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival. J Neurooncol. 2007;81:1-7.
29. Junck L, Olson JM, Ciliax BJ, Koeppe RA, Watkins GL, Jewett DM, et al. PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. Ann Neurol. 1989;26:752-8.
30. Pappata S, Cornu P, Samson Y, Prenant C, Benavides J, Scatton B, et al. PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. J Nucl Med. 1991;32:1608-10.
31. Takaya S, Hashikawa K, Turkheimer FE, Mottram N, Deprez M, Ishizu K, et al. The lack of expression of the peripheral benzodiazepine receptor characterises microglial response in anaplastic astrocytomas. J Neurooncol. 2007;85:95-103.
32. Badie B, Schartner JM, Paul J, Bartley BA, Vorpahl J, Preston JK. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg. 2000;93:634-9.
33. Kaur C, Dheen ST, Ling EA. From blood to brain: amoeboid microglial cell, a nascent macrophage and its functions in developing brain. Acta Pharmacol Sin. 2007;28:1087-96.
34. Drew PD, Chavis JA. Inhibition of microglial cell activation by cortisol. Brain Res Bull. 2000;52:391-6.
35. Cremer JE, Hume SP, Cullen BM, Myers R, Manjil LG, Turton DR, et al. The distribution of radioactivity in brains of rats given [N-methyl-11C]PK 11195 in vivo after induction of a cortical ischaemic lesion. Int J Rad Appl Instrum B. 1992;19:159-66.
36. Hong IK, Chung ST, Kim HK, Kim YB, Son YD, Cho ZH. Ultra fast symmetry and SIMD-based projection-backprojection (SSP) algorithm for 3-D PET image reconstruction. IEEE Trans Med Imaging. 2007;26:789-803.
37. Hinz R, Jones M, Bloomfield PM, Boellaard R, Turkheimer FE, Tyrrell PJ. Reference tissue kinetics extraction from [11C]-(R)-PK11195 scans on the High Resolution Research Tomograph (HRRT). Neuroimage. 2008;41:T65.
38. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration of PET and MR images of human brain. Neuroimage. 2004;22:434-42.
39. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839-51.
40. Hammers A, Chen CH, Lemieux L, Allom R, Vossos S, Free SL, et al. Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. Hum Brain Mapp. 2007;28:34-48.
41. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224-47.
42. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-9.
43. Anderson AN, Pavese N, Edison P, Tai YF, Hammers A, Gerhard A, et al. A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage. 2007;36:28-37.
44. Wyss MT, Hofer S, Hefti M, Bartschi E, Uhlmann C, Treyer V, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007;48:1047-52.
45. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol. 2005;71:161-8.
46. Imai Y, Kohsaka S. Intracellular signaling in M-CSF-induced microglia activation: role of Iba1. Glia. 2002;40:164-74.
47. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135-60.
48. Geistanger A, Berding C, Vorberg E, Herlan M. Local regression: a new approach for measurement system comparison analysis. Clin Chem Lab Med. 2008;46:1211-9.
49. Van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. Crit Rev Oncol Hematol. 2008;66:262-72.
50. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971-88.
51. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2005;26:266-73.
52. Folkersma H, Boellaard R, Yaqub M, Kloet RW, Windhorst AD, Lammertsma AA, et al. Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med. 2011;52:1235-9.
53. Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, et al. Microglial activation in healthy aging. Neurobiol Aging. 2012;33:1067-72.
54. Feeney DM, Baron JC. Diaschisis. Stroke. 1986;17:817-30.
55. Andrews RJ. Transhemispheric diaschisis. A review and comment. Stroke. 1991;22:943-9.
56. Shinonaga M, Chang CC, Suzuki N, Sato M, Kuwabara T. Immunohistological evaluation of macrophage infiltrates in brain tumors. Correlation with peritumoral edema. J Neurosurg. 1988;68:259-65.
57. Choi J, Nordli Jr DR, Alden TD, DiPatri Jr A, Laux L, Kelley K, et al. Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J Neuroinflammation. 2009;6:38.
58. Najjar S, Pearlman D, Miller DC, Devinsky O. Refractory epilepsy associated with microglial activation. Neurologist. 2011;17:249-54.